Bacillus Coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced colitis in mice

Gut Pathogens

Volumn 3, Issue 1, 2011, Pages

  Fitzpatrick, Leo R ^a   Small, Jeffrey S ^a   Greene, Wallace H ^a   Karpa, Kelly D ^a   Keller, David ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Ganeden Biotech Inc   (United States)

Author keywords

Clostridium difficile; colitis; mice; probiotics

Indexed keywords

EID: 84860670726     PISSN: None     EISSN: 17574749     Source Type: Journal    
DOI: 10.1186/1757-4749-3-16     Document Type: Article

References (20)

1. Clostridium difficile-associated diarrhea. Johnson S, Gerding DN, Clin Infect Dis 1998 26 1027 1034 10.1086/520276 9597221
2. Clostridium difficile colitis. Kelly CP, Pothoulakis C, Lamont JT, N Eng J Med 1994 330 257 262 10.1056/NEJM199401273300406 (Pubitemid 24034138)
3. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Pothoulakis C, Lamont JT, Am J Physiol Gastrointest Liver Physiol 2001 28 178 G183
4. Roles of intracellular calcium and NF-B in the clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes. Jefferson KK, Smith MF, Bobak DA, J Immunol 1999 165 5183 5191
5. NF-B activation pathway is essential for the chemokine expression in intestinal epithelial cells stimulated with clostridium difficile toxin A. Kim JM, Lee JY, Yoon YM, Oh YK, Youn J, Kim YJ, Scand J Immunol 2006 63 453 460 10.1111/j.1365-3083.2006.001756.x 16764699 (Pubitemid 43978860)
6. A mouse model of clostridium difficile-associated disease. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP, Gastroenterology 2008 135 1984 1992 10.1053/j.gastro.2008.09.002 18848941
7. Treatment of antibiotic-associated pseudomembranous colitis. Bartlett JG, Rev Infect Dis 1984 6 Suppl 1 235 S241 6718937
8. Treatment of recurrent clostridium difficile colitis with vancomycin and saccharomyces boulardii. Surawicsz CM, McFarland LV, Elmer G, Chinn J, Am J Gastroenterol 1989 84 1285 1287 2679049 (Pubitemid 19264721)
9. A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. McFarland LV, Surawicsz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al. JAMA 1994 271 1913 1918 10.1001/jama.271.24.1913 8201735 (Pubitemid 24177098)
10. The search for a better treatment for recurrent clostridium difficile disease: use of high-dose vancomycin combined with saccharomyces boulardii. Surawicsz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmaker S, Bowen K, Borjal D, Elmer GW, Clin Infect Di 2000 31 1012 1017 10.1086/318130 (Pubitemid 32299362)
11. Prevention of further recurrences of clostridium difficile colitis with saccharomyces boulardii. Kimmey MB, Elmer GW, Surawicsz CM, McFarland LV, Dig Dis Sci 1990 35 897 901 10.1007/BF01536805 2364845 (Pubitemid 20216461)
12. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C, Chang EB, Gastroenterology 2004 127 1474 1487 10.1053/j.gastro.2004.09.001 15521016 (Pubitemid 39457773)
13. Probiotics and the management of inflammatory bowel disease. Fedorak RN, Madsen KL, Inflam Bowel Dis 2004 10 286 299 (Pubitemid 38618261)
14. Physiological basis for novel drug therapies to treat the inflammatory bowel diseases: I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Shanahan F, Am J Physiol Gastrointest Liver Physiol 2005 28 417 G421
15. In vitro and in vivo effects of the probiotic Escherichia coli strain M-17: immunomodulation and attenuation of murine colitis. Fitzpatrick LR, Small J, Hoerr RA, Bostwick EF, Maines L, Koltun W, Br J Nutrit 2008 100 530 541
16. Effect of biotherapeutics on cyclosporin-induced clostridium difficile infection in mice. Kaur S, Vaishnavi C, Ray P, Kochhar R, Prasad KK, J Gastroenterol Hepatol 2010 25 832 838 10.1111/j.1440-1746.2009.06135.x 20074161
17. Bacillus coagulans as a probiotic. Keller D, Farmer S, McCartney AL, Gibson G, Food Science and Technology Bulletin: Functional Foods 2010 7 103 109 10.1616/1476-2137.16015
18. Gut Instinct: AIDS Healthcare Foundation Trains a Research Lens on Probiotics. Needle C, A&U Magazine, Albany NY 2010
19. Ganeden BC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. Jensen GS, Benson KF, Carter SG, Endres JR, BMC Immunol 2010 11 15 10.1186/1471-2172-11-15 20331905
20. Inflammation and apoptosis in Clostridium difficile enteritis is mediated by PGE2 up-regulation of Fas ligand. Kim H, Rhee SH, Pothoulakis C, Lamont JT, Gastroenterology 2007 133 857 866